NK cells and CAR-NK cells RNA silencing guide

Delivery efficiency and the viability cost

The lipofection efficiency reported for primary human NK cells is a property of the reagent and the cargo rather than of the cell. In one serum-free comparison a lipid-based siRNA transfection reagent delivered a labeled oligonucleotide to the great majority of unmanipulated primary human NK cells, at a viability its authors report as unaffected and with subset distribution, missing-self cytotoxicity and antibody-dependent killing unchanged, while the other reagents compared beside it, a cationic lipid reagent and nucleofection, reached far fewer cells. Uptake of a lipoplex is endocytic and its escape from the endosome depends on the reagent, which is why two reagents carrying the same cargo into the same cells do not deliver the same amount. How much of an electroporated NK culture survives depends on the cargo and on the medium the cells are recovered into, and surviving cells can show aberrant morphology and reduced cytotoxic capacity. Read delivery and viability in the same experiment, for the combination in hand, rather than from a figure measured with another.

High impact

Cytotoxic granule polarization and the killing readout

NK cells kill targets by polarizing lytic granules (containing perforin and granzymes) toward the immunological synapse and releasing contents into target cells. This requires the microtubule organizing center (MTOC) to polarize to the immunological synapse, directing granule movement along microtubules to the target contact site. Whether a delivery step costs any of that is measured rather than assumed. Read CD107a degranulation and killing of the standard target against an untreated control, and against the delivery step carrying no cargo, before a cytotoxicity result is attributed to the knockdown.

High impact

Premature activation and exhaustion

A delivery step is itself a candidate activating stimulus for an NK cell, and whether it activates one in a given preparation is read rather than assumed. Read the inhibitory receptors TIGIT, PD-1 and TIM-3, the activating receptors NKG2D, DNAM-1 and the natural cytotoxicity receptors, and degranulation, against an untreated control and against the delivery step carrying no cargo, at the time point the functional assay is read.

High impact

Donor-to-donor variability in primary NK cells

Transfection efficiency varies between donors in primary human NK cells, and part of that spread is a property of the protocol rather than of the donor: one electroporation optimization found the variability differed with the wash and electroporation buffer it used. Standardizing across donor preparations therefore means fixing the conditions and measuring each preparation, rather than predicting it from a donor's phenotype. NK cells are also heterogeneous within a single donor: CD56bright NK cells are the cytokine-producing minority, while CD56dim NK cells are the large majority of peripheral NK cells and are the cytotoxic subset.

Medium impact

CAR-NK manufacturing compatibility

CAR-NK cell manufacturing requires combining viral CAR transduction with genetic enhancements (checkpoint knockout, cytokine pathway modulation). Adding electroporation-based gene editing creates a triple insult: (1) viral transduction stress, (2) electroporation toxicity, (3) activation-induced exhaustion during expansion. This stacked toxicity reduces manufacturing yield, extends timelines, and produces CAR-NK cells with suboptimal function. Regulatory requirements for off-the-shelf CAR-NK (GMP manufacturing, cryopreservation, quality control) are incompatible with high-toxicity transfection methods.

High impact

NK-92 cell line limitations

NK-92 is the most extensively studied NK cell line in clinical trials and the primary platform for CAR-NK development. However, NK-92 cells are not spared: the viability cost of electroporating them depends on the cargo, a plasmid costing more of it than a ribonucleoprotein does, and the phenotype is altered post-transfection. Wild-type NK-92 naturally lacks CD16 expression (FcγRIII) and cannot perform ADCC, though engineered NK-92-CD16 variants address this limitation. Moreover, NK-92 requires irradiation before infusion (cannot proliferate in vivo), limiting persistence. Genetic engineering must preserve NK-92's cytotoxic capacity while maintaining safety profile.

Medium impact

Method comparison

AUMsilence™ sdASO™

Why AUMsilence™ sdASOs™ suit NK cells

Key benefits

• Viability for functional assays
  No cationic lipid is added and no pulse is applied, so the delivery step brings no membrane damage. Read viability against a non-targeting control before a cytotoxicity assay, a long-term co-culture, a serial tumor rechallenge or an in vivo xenograft. Viability is target-dependent; empirical validation required.
• Enables checkpoint blockade studies
  Silence inhibitory receptors (NKG2A/KLRC1, TIGIT, PD-1, KIRs) to model checkpoint blockade therapy. Measure enhanced tumor killing, increased IFN-γ production, improved persistence. Mimics clinical checkpoint antibodies (monalizumab anti-NKG2A) with genetic validation.
• Exhaustion prevention for enhanced persistence
  Knockdown CIS (CISH, enhances IL-15 signaling), TOX (prevents exhaustion), or inhibitory cytokine receptors (TGFβR2, IL-10R). Enhancement magnitude is target and cell-type dependent; empirical validation required for each application.
• CAR-NK optimization platform
  Combine AUMsilence sdASO checkpoint knockout with viral CAR transduction for synergistic enhancement. No interference with CAR expression. Can add before, during, or after transduction depending on strategy.
• Rapid timeline for target validation
  Test gene function in 3-5 days: isolate NK cells, add ASO, validate knockdown, perform functional assays. No viral vector cloning, no optimization of toxic transfection conditions. Accelerates hypothesis testing and target prioritization.
• ADCC mechanism studies
  Primary NK cells express CD16 (FcγRIII) for antibody-dependent cellular cytotoxicity. AUMsilence sdASO enables dissection of ADCC pathways: CD16 signaling components, activating receptor synergy, perforin/granzyme requirements. Read CD16 expression and ADCC function against a non-targeting control.

Cell types and applications

• Primary human NK cells (CD56+ from peripheral blood)
• NK-92 cell line and variants (NK-92MI, NK-92-CD16)
• CAR-NK cell engineering and optimization
• Checkpoint blockade studies (NKG2A, TIGIT, PD-1, KIRs)
• Exhaustion prevention (CIS/CISH, TOX knockdown)
• Activating receptor function studies (NKG2D, DNAM-1, NCRs)
• ADCC mechanism research (CD16, FcγR signaling)
• Innate immunity and viral defense (CMV, influenza, HIV)
• Cytotoxic granule biology (perforin, granzyme B, degranulation)
• NK cell metabolic reprogramming
• Allogeneic NK cell platform research
• NK cell exhaustion and tumor microenvironment resistance

• AUMsilence™ sdASO™

Alternative products

• AUMantagomir™ sdASO™ When to use: For microRNA inhibition in NK cells. Recommended for studying miR-155-5p, miR-27a-5p (targets perforin and granzyme B), and miR-150-5p (regulates c-Myb, important for NK development).
• Order AUMsilence™ sdASO™ When to use: For novel NK cell targets or CAR-NK enhancement panels. AUM scientists design and validate 3-5 ASO candidates per target, optimized for human sequences.

Optimized protocols for primary human NK cells, NK-92 cell line, and CAR-NK engineering. No transfection reagents required.

Quick start protocol (all NK cell types)

1. 01Culture NK cells at 0.5-1 × 10⁶ cells/mL in appropriate medium (RPMI + IL-2 for primary NK, Alpha-MEM for NK-92)
2. 02Add AUMsilence™ sdASO™ directly to culture at 10 μM (no transfection reagent)
3. 03Incubate 48-72 hours at 37°C, 5% CO₂
4. 04Validate knockdown by qRT-PCR (48h) and flow cytometry (72h)
5. 05Perform functional assays: cytotoxicity (51Cr release or flow-based), degranulation (CD107a), IFN-γ production

Cell-type-specific protocols

Primary human NK cells (CD56+ from PBMCs)

1. 01

   Step 1: NK cell isolation

   Isolate NK cells from PBMCs using negative selection with a commercially available magnetic bead-based NK cell isolation kit. Negative selection preserves surface receptors and activation state. Yield: 5-15% of PBMCs are NK cells (CD3-CD56+ or CD3-CD16+). For higher purity, perform CD56 positive selection after negative enrichment. Note: CD56bright cells are a minority and are cytokine producers; CD56dim cells are the large majority and are cytotoxic.

   Materials: RPMI-1640 + 10% FBS + 1% Pen/Strep + recombinant human IL-2 (100-200 U/mL)

   Note: IL-2 essential for NK cell survival and expansion. Primary NK cells do not proliferate extensively (limited expansion, 2-4 fold over 7 days).

   Timing: Day 0

2. 02

   Step 2: NK cell culture and expansion

   Seed freshly isolated NK cells at 0.5-1 × 10⁶ cells/mL in complete RPMI + IL-2 (100 U/mL). Culture in T-25 flask or 24-well plate (suspension culture). NK cells maintain viability for 7-14 days with IL-2 supplementation. Optional: add IL-15 (10 ng/mL) for enhanced survival and expansion.

   Materials: RPMI-1640 + IL-2 (+ optional IL-15)

   Note: Primary NK cells are fragile; handle gently, avoid excessive pipetting. Monitor density (split if exceeding 2 × 10⁶/mL).

   Timing: Day 0-2

3. 03

   Step 3: AUMsilence sdASO treatment

   At Day 2-3 post-isolation (rested NK cells), add AUMsilence sdASO directly to culture at 10 μM. For 500 μL culture (24-well), add 5 μL of 1 mM AUMsilence sdASO stock. No media change required. AUMsilence sdASOs are chemically modified for self-delivery, with no transfection reagent.

   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)

   Note: Maintain IL-2 throughout ASO treatment (do not remove). The oligonucleotide is taken up by IL-2-activated NK cells.

   Timing: Day 2-3

4. 04

   Step 4: Incubation and monitoring

   Incubate 48-72h at 37°C, 5% CO₂. Monitor cell density and viability daily. Viability and knockdown efficiency are target-dependent; empirical validation required for each application. NK cells remain in suspension. Do not change medium unless a specific assay requires it.

   Materials: Humidified CO₂ incubator

   Note: mRNA knockdown is typically achieved 24-72 hours after treatment. Functional assays typically performed at 72-96h post-ASO.

   Timing: Days 2-5

5. 05

   Step 5: Validation and functional assays

   At 48h: qRT-PCR for mRNA knockdown (target-dependent; empirical validation required). At 72h: flow cytometry for surface receptors (NKG2A, TIGIT, NKG2D, CD16/FcγRIIIA) or intracellular proteins (perforin, granzyme B, granzyme K, CIS, TOX). Functional assays at 72-96h: (1) Cytotoxicity: co-culture with tumor targets (K562, 721.221, other tumor lines) at E:T ratios (10:1, 5:1, 1:1), measure target lysis by 51Cr release, flow-based viability (7-AAD, Annexin V), or real-time cell analyzer, (2) Degranulation: CD107a/LAMP-1 surface expression upon target encounter (4h co-culture with monensin/GolgiStop), (3) Cytokine production: IFN-γ, TNF-α ELISA or intracellular cytokine staining.

   Materials: Flow antibodies, target tumor cells, cytotoxicity assay reagents, ELISA kits

   Note: Read NK cytotoxic function against a non-targeting control. Enhancement magnitude from checkpoint or CIS knockdown is target and cell-type dependent; empirical validation required for each application.

   Timing: Days 4-6

NK-92 cell line

1. 01

   Step 1: NK-92 culture

   Culture NK-92 in Alpha-MEM medium (no nucleosides) + 12.5% horse serum + 12.5% FBS + 0.1 mM 2-mercaptoethanol + recombinant human IL-2 (200 U/mL). NK-92 grows in suspension, doubling every 24-48h. Maintain at 2-8 × 10⁵ cells/mL. Split 1:2 every 2-3 days.

   Materials: Alpha-MEM + horse serum + FBS + IL-2

   Note: NK-92 is IL-2-dependent cell line. Without IL-2, cells die within 24-48h. Cannot use RPMI (nutritional requirements different). Note: Wild-type NK-92 lacks CD16 (FcγRIII); use NK-92-CD16 variant for ADCC studies.

   Timing: Maintain stock culture

2. 02

   Step 2: AUMsilence sdASO treatment of NK-92

   Seed NK-92 at 5 × 10⁵ cells/mL in fresh medium 24h before ASO treatment. Add AUMsilence sdASO at 10 μM (or test across 5-20 μM). AUMsilence sdASOs are self-delivering, so cellular uptake needs no transfection reagent. Knockdown efficiency is target-dependent; empirical validation required. Continue culture with IL-2.

   Materials: AUMsilence sdASO

   Note: NK-92 may be more sensitive than primary NK cells. Higher consistency than primary cells (no donor variability).

   Timing: Day 0-3

3. 03

   Step 3: Validation and functional testing

   Validate knockdown at 48h (qRT-PCR) and 72h (flow/Western). NK-92 useful for: mechanistic studies (receptor function, signaling pathways), screening (test multiple targets rapidly), CAR-NK platform (combine ASO with lentiviral CAR transduction).

   Materials: Standard validation reagents

   Note: Wild-type NK-92 does not express CD16 (FcγRIII); cannot perform ADCC. For ADCC studies, use primary NK cells or engineered NK-92-CD16 variant.

   Timing: Days 2-3

CAR-NK cell engineering and enhancement

1. 01

   Step 1: NK cell preparation

   Start with primary NK cells (isolated from PBMCs) or NK-92 cell line. Expand in IL-2 (and IL-15 for primary cells) for 2-3 days to achieve sufficient cell numbers for transduction and treatment.

   Materials: RPMI or Alpha-MEM + IL-2 + IL-15 (primary only)

   Note: For in vivo work: primary NK cells preferred (can persist in vivo). For in vitro work: NK-92 simpler (no donor variability).

   Timing: Day 0-3

2. 02

   Step 2: Pre-transduction checkpoint knockout (strategy 1)

   Option 1: Add AUMsilence sdASO targeting checkpoint receptors (NKG2A, TIGIT, PD-1) at Day 2-3 before CAR transduction. Allow 24-72 hours for knockdown. Then proceed with lentiviral or retroviral CAR transduction (MOI 3-10). ASO does not interfere with viral transduction. This creates checkpoint-resistant phenotype before CAR introduction.

   Materials: AUMsilence sdASO (10 μM), CAR lentiviral vector

   Note: Pre-transduction knockdown establishes checkpoint resistance before CAR expression. Useful for NKG2A-HLA-E axis blockade (many tumor cells express HLA-E).

   Timing: Day 2-5

3. 03

   Step 3: Post-transduction enhancement (strategy 2)

   Option 2: Transduce NK cells with CAR vector first (Day 3-4), expand for 5-7 days to establish CAR expression, then add AUMsilence sdASO (Day 8-10) to prevent exhaustion or enhance function. Targets: CIS (CISH, enhances IL-15 signaling), TOX (prevents exhaustion), inhibitory cytokine receptors (TGFβR2, IL-10R). This optimizes CAR-NK function after CAR expression established.

   Materials: AUMsilence sdASO (10 μM)

   Note: The ASO goes on after the CAR is already expressed. Validate the CAR+ percentage before and after the ASO, against the untreated arm.

   Timing: Day 8-11

4. 04

   Step 4: CAR-NK expansion

   Expand CAR-NK cells for 7-14 days post-transduction with IL-2 + IL-15. Monitor CAR expression (flow cytometry with Protein L or CAR-specific reagent), checkpoint receptor expression (NKG2A, TIGIT; should be reduced if knocked down), and viability. Re-dose AUMsilence sdASO every 3 to 5 days if sustained knockdown is desired.

   Materials: IL-2, IL-15, flow antibodies

   Note: CAR-NK cells undergo moderate proliferation (3-10 fold expansion over 7-14 days). ASO dilution slower than CAR-T (less division).

   Timing: Days 5-14

5. 05

   Step 5: CAR-NK functional validation

   Validate enhanced CAR-NK function: (1) CAR-dependent killing: co-culture with CAR antigen-positive tumor cells, measure cytotoxicity at various E:T ratios, (2) Innate killing preserved: co-culture with CAR antigen-negative but NK-sensitive targets (K562), confirm NK cell function maintained, (3) Checkpoint resistance: for NKG2A knockdown, test killing of HLA-E-expressing tumor cells against the control, (4) Persistence: long-term co-culture with tumor cells (serial rechallenge), measure CAR-NK persistence and exhaustion markers.

   Materials: Tumor cell lines (CAR antigen+ and antigen-), K562 cells, flow cytometry

   Note: CAR-NK advantage: dual killing mechanisms (CAR-mediated + innate NK). Checkpoint knockout enhances both pathways.

   Timing: Days 12-16

NK cell exhaustion prevention

1. 01

   Step 1: CIS (CISH) knockdown for enhanced cytokine responsiveness

   CIS (cytokine-inducible SH2-containing protein, encoded by CISH gene) is a member of the SOCS family that negatively regulates JAK-STAT signaling downstream of IL-15 and IL-2 receptors. IL-15 is the physiologically relevant cytokine for NK cell survival and function in vivo (IL-2 is primarily used ex vivo). CIS acts by: (1) targeting phosphorylated JAK proteins for proteasomal degradation via its SOCS box domain, (2) blocking STAT5 recruitment to cytokine receptor docking sites. CIS knockout NK cells show enhanced IL-15 signaling, STAT5 phosphorylation, proliferation, persistence, and anti-tumor activity in preclinical models. Add AUMsilence sdASO targeting CISH at 10 μM to rested NK cells (Day 2-3 post-isolation). Incubate 48-72h.

   Materials: AUMsilence sdASO anti-CISH

   Note: CIS knockdown is a well-validated NK cell enhancement strategy in preclinical research. CIS is upregulated in NK cells exposed to chronic inflammation and acts as a checkpoint limiting NK fitness and cytotoxicity. CIS knockdown (via genetic methods) showed partial functional rescue in preclinical models. CISH-knockout NK cells show enhanced IL-15 signaling, improved expansion, increased metabolic fitness, and greater anti-tumor activity in preclinical mouse models.

   Timing: Day 2-5

2. 02

   Step 2: Validation of CIS knockdown effects

   Measure enhanced IL-15 responsiveness: (1) Proliferation: CFSE dilution in presence of IL-15 (often shows increased divisions with CIS knockdown), (2) STAT5 phosphorylation: stimulate with IL-15, measure phospho-STAT5 by flow cytometry (typically shows enhanced signaling), (3) Survival: culture with limiting IL-15 concentrations, measure viability over 7-14 days (CIS-knockout NK cells often survive better), (4) Anti-tumor activity: cytotoxicity assays against tumor cells (target and cell-type dependent; empirical validation required).

   Materials: IL-15, CFSE, phospho-STAT5 antibody, tumor targets

   Note: CIS knockdown can be particularly valuable for extending NK cell persistence in vivo (mouse xenograft models) and during ex vivo expansion.

   Timing: Days 5-10

3. 03

   Step 3: TOX knockdown for exhaustion prevention

   TOX transcription factor drives NK cell exhaustion similar to T cell exhaustion. Knockdown TOX in NK cells undergoing chronic stimulation (repeated tumor encounter, prolonged cytokine exposure). Measure exhaustion markers (PD-1, TIGIT, LAG-3 upregulation reduced) and maintained cytotoxicity.

   Materials: AUMsilence sdASO anti-TOX

   Note: TOX knockdown emerging strategy for NK and CAR-NK. Less validated than CIS but promising for preventing tumor-induced exhaustion.

   Timing: Day 2-10

Essential controls for NK cell experiments

• Untreated NK cells: Baseline cytotoxicity, receptor expression, degranulation capacity
  Culture identically but without ASO addition. Critical for demonstrating no functional impairment from ASO treatment itself.
• Non-targeting control ASO: Control for non-specific ASO effects on NK cell biology
  Use AUM non-targeting control at 10 μM. Verifies target specificity and rules out innate immune activation from phosphorothioate backbone.
• Positive control target (K562 or 721.221 cells): Validate baseline NK cell cytotoxic function
  K562 is MHC Class I-deficient chronic myelogenous leukemia line; highly sensitive to NK cell killing. 721.221 is HLA Class I-negative B-lymphoblastoid line. Use as positive control for cytotoxicity assays (typically >50% lysis at 10:1 E:T ratio, target and cell-type dependent).
• Electroporation comparison: Optional. Compare electroporation with AUMsilence sdASO in the same experiment
  Electroporate NK cells with control oligonucleotide. Measure viability and cytotoxicity, both of which can fall. Compare to AUMsilence sdASO in the same experiment.

Optimization strategies for NK cell applications

Troubleshooting

Quantitative RT-PCR (qRT-PCR)

Flow cytometry (surface and intracellular proteins)

Cytotoxicity assays (tumor killing)

Degranulation assay (CD107a expression)

IFN-γ production (ELISA and intracellular flow)

Critical controls for NK cell validation

• Untreated NK cells
  Purpose: Baseline cytotoxicity, receptor expression, degranulation, IFN-γ production
  Culture identically without ASO. Essential for reading whether the ASO changes function.
• Non-targeting control ASO
  Purpose: Control for non-specific ASO effects
  Use AUM non-targeting control at 10 μM. Verifies target specificity and rules out innate immune activation from phosphorothioate backbone. NK cells express TLR9 (recognizes unmethylated CpG); non-targeting control essential.
• K562 or 721.221 target cells (positive control)
  Purpose: Validate baseline NK cell function independent of checkpoint receptors
  K562 is MHC Class I-deficient chronic myelogenous leukemia line, HLA-E-negative; no inhibitory signals through KIR or NKG2A. 721.221 is HLA Class I-negative B-lymphoblastoid line. Both highly sensitive to NK killing. Typically >50% lysis at 10:1 E:T ratio (cell-type dependent). If killing of these targets is reduced, NK cells may have intrinsic functional defect (not checkpoint-related).
• Dose-response and sequence verification
  Purpose: Confirm concentration-dependent knockdown and target specificity
  Test 5 μM, 10 μM and 20 μM ASO; knockdown should correlate. Design 3-5 independent ASO sequences targeting different regions; concordant phenotypes confirm on-target effect (gold standard for specificity).

Best practices

• Use biological replicates (n=3 independent experiments, different donor PBMCs for primary NK cells)
• Validate knockdown at both mRNA (qRT-PCR, 48h) and protein (flow, 72h) levels
• Maintain IL-2 throughout experiments (100-200 U/mL for survival)
• For functional assays, verify knockdown in same cells used for assay (not separate aliquot)
• Use low E:T ratios (1:1, 3:1) to detect enhancement; high ratios show ceiling effects
• Include K562 positive control in all cytotoxicity assays (baseline NK function)
• Report viability, cell number, and NK cell purity (CD56+CD3-) in all publications